Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2017 05/17/2017 05/18/2017 05/19/2017 05/22/2017 Date
14.75(c) 14.1(c) 14.6(c) 14.25(c) 14.2 Last
424 373 726 529 487 052 331 996 278 504 Volume
+2.08% -4.41% +3.55% -2.40% -0.35% Change
More quotes
Financials ($)
Sales 2017 167 M
EBIT 2017 -26,1 M
Net income 2017 -21,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 201 M
EBIT 2018 -4,55 M
Net income 2018 -5,22 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,79x
Capi. / Sales2018 3,16x
Capitalization 635 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
05/11 VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 42nd Annual Health Care ..
05/03 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
05/03 VANDA PHARMACEUTICALS : reports 1Q loss
05/02 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
05/02 VANDA PHARMACEUTICALS : Reports First Quarter 2017 Financial Results
05/01 VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 42nd Annual Health Care ..
04/20 VANDA PHARMACEUTICALS : Patent Issued for Metabolites of (1R-Trans)-N-methyl]pro..
04/20 VANDA PHARMACEUTICALS : to Announce First Quarter 2017 Financial Results on May ..
04/13 VANDA PHARMACEUTICALS : to Announce First Quarter 2017 Financial Results on May ..
04/13 VANDA PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Kansas (April 13)
More news
Sector news : Bio Therapeutic Drugs
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
More sector news : Bio Therapeutic Drugs
Latest Tweets
05/17Vanda Pharmaceuticals Inc. $VNDA Upgraded at TheStreet  
05/17Vanda Pharmaceuticals upgraded by TheStreet to c-.  
05/16Vanda Pharmaceuticals Inc. $VNDA Expected to Announce Earnings of -$0.20 Per .. 
05/10Want the latest upgrades & downgrades for $ACLZ $KALV $VNDA $DLTR $MMYT? .. 
05/10Commentary On Great Point Partners' Positions Part 1  
More tweets
Qtime:14
News from SeekingAlpha
05/10 Commentary On Great Point Partners' Positions Part 1
05/05 After Hours Gainers / Losers
05/02 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2017 Results - ..
05/01 Notable earnings after Tuesday?s close
03/22 Vanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare C..
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 22,0 $
Spread / Average Target 54%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-10.66%635
AMGEN, INC.7.04%115 097
CELGENE CORPORATION1.02%91 302
GILEAD SCIENCES, INC.-10.31%83 931
REGENERON PHARMACEUTIC..22.59%47 832
ACTELION LTD24.04%30 542
More Results